Sailong Pharmaceutical Group (002898.SZ) announced on July 1st that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the approval and issuance of the approval notice for the listing application of chemical raw materials for Fosaprepitant Dimeglumine by the National Medical Products Administration.
The main indication of Fosaprepitant Dimeglumine is to be used in combination with other antiemetic drugs. It is suitable for the prevention of acute and delayed nausea and vomiting that occur during the use of highly emetogenic antineoplastic chemotherapy drugs (HEC), including high-dose cisplatin, in children aged 6 months and older and adult patients; and for the prevention of acute and delayed nausea and vomiting that occur during the use of moderately emetogenic antineoplastic chemotherapy drugs (MEC) for the first time or repeatedly.
